Topline results from the SURPASS-CVOT trial show that once-weekly tirzepatide has a cardiovascular risk profile similar to ...

In patients with type 2 diabetes and CVD, the GIP/GLP-1 agonist was as good as the older drug, and possibly better in some ...

Once-weekly tirzepatide conferred a similar cardiovascular risk as once-weekly dulaglutide in adults with type 2 diabetes and ...

SURPASS-CVOT evaluated the efficacy and safety of tirzepatide compared with dulaglutide in adults with T2D and a confirmed ASCVD.

Eli Lilly (NYSE:LLY) announced Thursday that its diabetes therapy, Mounjaro (tirzepatide), succeeded in a late-stage trial ...

A recent study shows the use of GLP-1 drugs can increase the risk for optic nerve damage in the first year of treatment, ...

Dulaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist In AWARD-7, eligible patients (N=577) were randomized to receive dulaglutide 1.5mg once-weekly (N=193), dulaglutide 0 ...

Women who quit smoking and were treated with the GLP-1 receptor agonist dulaglutide were less likely to experience substantial weight gain compared with those who received placebo, according to ...

Dulaglutide injection should be given subcutaneously in the abdomen, thigh or upper arm once e every week at any time of the day. The initial dose is 0.75 mg once a week.

From a mean baseline HbA 1c of 8.2%, 0.5 mg semaglutide achieved a statistically significant and superior reduction of 1.5% compared with a reduction of 1.1% with 0.75 mg dulaglutide. People ...

INDIANAPOLIS, May 8, 2020 /PRNewswire/ -- New 36-week data showed higher investigational doses of Trulicity (3 mg and 4.5 mg) were well-tolerated and led to A1C reductions up to 1.9 percent and ...

British Columbia's Ministry of Health is limiting the sales of two more diabetes drugs to curb their off-label use for weight loss and preserve supply for people who are diabetic.